Position in MSLE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,817,432
New position
Shares Held
500,432
first reported quarter
Ownership
2.40%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Woodline Partners LP holds $3,316,203,980 across 189 Biotechnology names. MSLE ranks #134 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
2,506,570 | $243,763,932 | |
| 2 | TNGX |
Tango Therapeutics, Inc.
|
8,000,013 | $167,360,271 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
1,414,173 | $149,053,834 | |
| 4 | RCUS |
Arcus Biosciences, Inc.
|
3,777,798 | $81,600,436 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
243,883 | $80,693,568 | |
| 6 | SRRK |
Scholar Rock Holding Corp
|
1,500,470 | $73,763,105 | |
| 7 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
758,891 | $66,000,750 | |
| 8 | CYTK |
Cytokinetics Inc
|
1,000,428 | $65,938,209 |
All Filings in MSLE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,817,432 | 500,432 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||